Publications
Publishing the Frontiers of Immuno-Oncology
Spotlight Publication
Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)
Emerging survival plateaus with botensilimab and balstilimab: Pan tumor data from a large phase 1b trial of advanced solid tumors
Oct 17, 2025
,
Gordon et al.
ESMO
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Balstilimab (PD-1 inhibitor)
Botensilimab (Fc-enhanced anti-CTLA-4)
Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer.
ESMO
European Society for Medical Oncology, Gastrointestinal (ESMO- GI)
July 28, 2022
,
Bullock, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)
AgenT-797, a native allogeneic “off-the-shelf” iNKT cell therapy product shows anti-tumor activity in preclinical xenograft models.
SITC
Society for Immunotherapy of Cancer (SITC)
June 2, 2022
,
Yigit, et al.
No items found.
AGENT-797 (Allogeneic iNKT Cell Therapy)
AgenT-797, a novel allogenic and “off-the shelf” iNKT cell therapy promotes effective tumor killing.
SITC
Society for Immunotherapy of Cancer (SITC)
June 2, 2022
,
Burcu, et al.
No items found.
INCAGN2385 (LAG-3 Antagonist)
INCAGN02385 is an Antagonist Antibody Targeting the Co-Inhibitory Receptor LAG-3 for the Treatment of Human Malignancies.
AACR
American Association for Cancer Research (AACR)
June 2, 2022
,
Savitsky, et al.
No items found.